Prospective, randomized, open-label, clinical trial comparing standard and intensive LDL-lowering therapies using rosuvastatin on progression of atherosclerotic plaques, endothelial function, markers for anti-inflammatory properties/obesity/antioxidative properties.

Trial Profile

Prospective, randomized, open-label, clinical trial comparing standard and intensive LDL-lowering therapies using rosuvastatin on progression of atherosclerotic plaques, endothelial function, markers for anti-inflammatory properties/obesity/antioxidative properties.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Rosuvastatin (Primary)
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Feb 2013 Results presented at the 38th International Stroke Conference.
    • 30 Nov 2012 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top